News

​A drug candidate has been found in preclinical trials to stop tumor growth entirely, deliver more cancer-busting power than many commonly used chemotherapy drugs and do so with fewer toxic side effects and more ability to overcome resistance.

Two faculty members from the University of Texas at Austin have received 2020 Sloan Research Fellowships, which honor outstanding early-career scientists in eight fields.

Carlos Baiz, assistant professor of chemistry at The University of Texas at Austin, has been named a 2020 Cottrell Scholar by the Research Corporation for Science Advancement (RCSA).

An international team of researchers that includes undergraduate chemistry student Annie Zhang from The University of Texas at Austin has found that aromatic compounds from auto emissions play a key role in the creation of tiny airborne particles that pose a significant health problem in many urban areas of the world.

The National Academy of Engineering (NAE) will bestow University of Texas at Austin professor C. Grant Willson with the Charles Stark Draper Prize for Engineering — widely regarded as the highest honor in the profession — for his pioneering work enabling the extreme miniaturization of microelectronic devices.

Out of the lab and into the marketplace. That could be the catch phrase for a growing number of UT Austin science students and faculty. They are pouring creativity and hard work into new efforts to bring UT science into new realms.

As we look back on 2019, it's been a year filled with fascinating discoveries and big developments in the College of Natural Sciences and beyond. Read on to see some of the highlights from this year in Texas Science.

Eric Anslyn, Edward Marcotte and George Georgiou were honored at an event this month honoring the top innovations and inventions of the year to come out of The University of Texas at Austin.

A widely used class of chemotherapy drugs, called topoisomerase inhibitors, come with some serious downsides: bone marrow damage, reduced blood cell production, diarrhea and heart damage. And some cancers can quickly develop resistance. A new discovery about a second class of drugs might lead to combination therapies that are just as effective, but with fewer downsides.